Pharmaceutical

Kymera’s novel MDM2 degrader granted orphan designation for AML

Kymera Therapeutics has announced that the FDA has granted KT-253 orphan drug designation for treating acute myeloid leukaemia.

Jun 23, 2023 - 20:00
Kymera’s novel MDM2 degrader granted orphan designation for AML
Kymera Therapeutics has announced that the FDA has granted KT-253 orphan drug designation for treating acute myeloid leukaemia.
Read the original article

Tags:

Previous Article

Talaris Therapeutics to merge with Tourmaline Bio

Next Article

Coherus Expands Beyond Biosimilars with $65M Acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ocular Therapeutix gets grant for intracanalicular inje...

Aug 23, 2024

Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry

Leading innovators in anti-influenza antibody compositi...

May 8, 2023

Morning Rounds: For kids with high BMI, task force not ready to recommend weight loss drugs

Morning Rounds: For kids with high BMI, task force not ...

Dec 13, 2023